Interleukin-1β, C-X-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 11, 2010, Pages 835-842

  Antonelli, Alessandro ^a   Ferri, Clodoveo ^b   Ferrari, Silvia Martina ^a   De Marco, Salvatore ^c   Di Domenicantonio, Andrea ^a   Centanni, Marco ^d   Pupilli, Cinzia ^e   Villa, Erica ^f   Menichetti, Francesco ^g   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CISANELLO HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID DERIVATIVE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; LOW DRUG DOSE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; CHEMOKINE CXCL10; CRYOGLOBULINEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; THYROIDITIS, AUTOIMMUNE;

HEPATITIS C VIRUS;

EID: 78149332071     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0024     Document Type: Article

References (41)

1. Abel G, Zhang QX, Agnello V. 1993. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 36(10): 1341-1349.
2. Akyuz F, Polat N, Kaymakoglu S, Aksoy N, Demir K, Besisik F, Badur S, Cakaloglu Y, Okten A. 2005. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels. World J Gastroenterol 11(45):7188-7191.
3. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. 2006a. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93(10):1226-1231.
4. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. 2008a. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 42(1):137-143.
5. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. 2008b. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 103(10):2488-2494.
6. Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, Fadda P, Pampana A, Maccheroni M, Ferrannini E. 2004a. Thyroid involvement in patients with overt HCVrelated mixed cryoglobulinaemia. QJM 97(8):499-506.
7. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. 2004b. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 43(2):238-240.
8. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. 2008c. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 8(1):18-23.
9. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. 2009. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 5(1):26-34.
10. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. 2004c. Thyroid disorders in chronic hepatitis C. Am J Med 117(1):10-13.
11. Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, Romagnani P, Serio M, Ferrannini E. 2006b. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 34(1-2):32-38.
12. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. 2007. Iodine- 131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92(4):1485-1490.
13. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. 2004d. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89(11):5496-5499.
14. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. 2005. Increase of interferon- gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152(2):171-177.
15. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. 2006c. Interferongamma- inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator- activated receptor-gamma agonists. J Clin Endocrinol Metab 91(2):614-620.
16. Apolinario A, Majano PL, Lorente R, Núñ ez O, Clemente G, García-Monzón C. 2005. Gene expression profile of T-cellspecific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepat 12(1):27-37.
17. Chantry D, Winearls CG, Maini RN, Feldmann M. 1989. Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon- gamma and tumor necrosis factor-alpha. Eur J Immunol 19(1):189-192.
18. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87(6):2095-2147.
19. Ferri C, La Civita L, Longombardo G, Greco F, Bombardieri S. 1993. Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest 23(7):399-405.
20. Ferri C, Mascia MT. 2006. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18(1):54-63.
21. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. 2004. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33(6):355-374.
22. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. 2001. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3p lymphocytes. J Clin Endocrinol Metab 86(10):5008-5016.
23. Gianoukakis AG, Jennings TA, King CS, Sheehan CE, Hoa N, Heldin P, Smith TJ. 2007. Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology 148(1):54-62.
24. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, Franklin EC. 1980. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69(2):287-308.
25. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. 2003. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 74(3):360-369.
26. Hunter CA, Chizzonite R, Remington JS. 1995. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 155(9):4347-4354.
27. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP. 2003. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59(2):207-213.
28. Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, di Marco R, Signorelli S, Scalia G, Zignego AL, de Re V, Mazzarino MC, Nicoletti F. 2006. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep 15(5):1305-1308.
29. Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J, Proost P. 2006. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest 86(9):902-916.
30. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. 1985. Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol 135(6):3962-3968.
31. Papanas N, Papazoglou D, Papatheodorou K, Antonoglou C, Kotsiou S, Maltezos E. 2006. Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin- 6. Cytokine 35(3-4):166-170.
32. Ramos-Casals M, Brito-Zerón P, Muñ oz S, Soto MJ; Biogeas Study Group. 2008. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345-364.
33. Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R, Visvanathan K. 2006. Toll-like receptor expression in chronic hepatitis C: correlation with proinflammatory cytokine levels and liver injury. Inflamm Res 55(7):279-285.
34. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M. 2001. Cell cycle- dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107(1):53-63.
35. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M. 2002. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/ CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 161(1):195-206.
36. Saadoun D, Bieche I, Authier FJ, Laurendeau I, Jambou F, Piette JC, Vidaud M, Maisonobe T, Cacoub P. 2007. Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 56(4):1315-1324.
37. Sims JE, Smith DE. 2003. Regulation of interleukin-1 activity is enhanced by cooperation between the interleukin-1 receptor type II and interleukin-1 receptor accessory protein. Eur Cytokine Netw 14(2):77-81.
38. Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A, Bartolozzi C, Pinchera A, Martino E. 1995. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest 18(11):857-861.
39. Wewers MD, Dare HA, Winnard AV, Parker JM, Miller DK. 1997. IL-1 beta-converting enzyme (ICE) is present andfunctional in human alveolar macrophages: macrophage IL-1 beta release limitation is ICE independent. J Immunol 15(12): 5964-5972.
40. Yeruva S, Ramadori G, Raddatz D. 2008. NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. Int J Colorectal Dis 23(3):305-317.
41. Zignego AL, Deny P, Feray C, Ponzetto A, Gentilini P, Tiollais P, Bréchot C. 1990. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes 4(1):43-51.